…
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
| Income before tax | -2.54M | -1.45M | -1.63M | -2.23M | - |
| Net income | -2.54M | -1.45M | -1.63M | -2.03M | 10.10M |
| Selling general administrative | 1.88M | 0.62M | 0.88M | 1.04M | 2.39M |
| Gross profit | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Ebit | -2.55M | -1.52M | -1.98M | -2.20M | - |
| Operating income | -2.55M | -1.52M | -1.98M | -2.20M | - |
| Interest expense | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 2.55M | 1.52M | 1.98M | 2.20M | - |
| Cost of revenue | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Total other income expense net | 0.00M | 0.07M | 0.35M | -0.03M | - |
| Discontinued operations | - | - | - | 0.20M | - |
| Net income from continuing ops | -2.54M | -1.45M | -1.63M | -2.23M | - |
| Net income applicable to common shares | -2.54M | -1.45M | -1.63M | -2.03M | - |
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
| Total assets | 0.01M | 0.10M | 0.58M | 2.19M | 3.55M |
| Other current assets | - | 0.05M | 0.06M | 0.05M | - |
| Total liab | 5.68M | 3.22M | 2.25M | 2.31M | 1.89M |
| Total stockholder equity | -5.66M | -3.12M | -1.68M | -0.12M | 1.66M |
| Other current liab | 0.45M | 0.01M | 0.09M | 0.32M | 1.29M |
| Common stock | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -25.90M | -23.36M | -21.91M | -20.28M | - |
| Other liab | 0.70M | - | - | - | - |
| Other assets | - | - | - | - | 0.00M |
| Cash | 0.01M | 0.04M | 0.51M | 2.13M | 3.52M |
| Total current liabilities | 4.98M | 3.22M | 2.25M | 2.31M | 1.89M |
| Short term debt | 0.21M | 0.01M | 0.08M | 0.17M | - |
| Short long term debt | 0.21M | 0.01M | 0.08M | 0.17M | - |
| Property plant equipment | - | 0.00M | 0.00M | 0.01M | 0.02M |
| Total current assets | 0.01M | 0.10M | 0.57M | 2.18M | - |
| Net tangible assets | -5.66M | -3.12M | -1.68M | -0.12M | - |
| Accounts payable | 1.67M | 1.27M | 0.93M | 0.82M | 0.51M |
| Breakdown | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 |
| Change to liabilities | 0.41M | 0.33M | 0.12M | 0.31M | - |
| Total cashflows from investing activities | - | - | - | 0.20M | 5.92M |
| Net borrowings | 0.20M | 0.20M | -0.06M | -0.06M | - |
| Total cash from financing activities | 0.20M | 0.20M | -0.06M | 0.01M | - |
| Change to operating activities | 1.91M | 0.71M | 0.16M | 0.04M | - |
| Net income | -2.54M | -1.45M | -1.63M | -2.03M | 10.10M |
| Change in cash | -0.03M | -0.47M | -1.61M | -1.40M | - |
| Total cash from operating activities | -0.23M | -0.47M | -1.55M | -1.61M | - |
| Depreciation | 0.00M | 0.00M | 0.01M | 0.01M | - |
| Other cashflows from investing activities | - | - | - | 0.20M | 5.92M |
| Change to account receivables | - | - | - | 0.01M | 0.05M |
| Sale purchase of stock | - | - | 0.00M | 0.01M | - |
| Change to netincome | -0.01M | -0.07M | -0.21M | 0.06M | - |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-1.05 2.58% |
39.65 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.46 0.65% |
537.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-11.46 1.20% |
946.29 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.
| Name | Title | Year Born |
|---|---|---|
| Dr. Alexander L. Weis Ph.D. | Chairman, CEO, Pres, CFO, Principal Accounting Officer and Sec. | 1950 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.